Küpeli Serhan
Pediatric Oncology Unit, Diyarbakir Children's Diseases Hospital, Yenisehir, Diyarbakir, Turkey.
Pediatr Hematol Oncol. 2012 Apr;29(3):293-8. doi: 10.3109/08880018.2011.622833. Epub 2012 Feb 3.
Treating infantile hemangiomas may be associated with significant morbidity. Recently, propranolol, a nonselective β-blocker, has become a reputed and successful treatment modality for infantile hemangiomas. Here, the author presents experience with oral propranolol in treatment of 14 patients with infantile hemangiomas. The drug was tolerated well and no side effects except reversible bronchospasm in 3 were observed during treatment. Eleven of the patients, younger than 1 year, showed a good response, with more than 50% reduction in the size of the hemangiomas. Although there are a limited number of patients, these results showed that oral propranolol therapy is a safe and effective choice in the treatment of infantile hemangiomas before the age of 1 year.
治疗婴儿血管瘤可能会伴有显著的发病率。最近，普萘洛尔，一种非选择性β受体阻滞剂，已成为一种著名且成功的婴儿血管瘤治疗方式。在此，作者介绍了口服普萘洛尔治疗14例婴儿血管瘤患者的经验。该药物耐受性良好，治疗期间除3例出现可逆性支气管痉挛外未观察到其他副作用。11例年龄小于1岁的患者反应良好，血管瘤大小缩小超过50%。尽管患者数量有限，但这些结果表明口服普萘洛尔疗法是1岁前婴儿血管瘤治疗的一种安全有效的选择。
